Last reviewed · How we verify

Deferiprone oral solution

ApoPharma · FDA-approved active Small molecule Quality 5/100

Deferiprone oral solution is a Small molecule drug developed by ApoPharma. It is currently FDA-approved. Also known as: DFP, Deferiprone extended release tablet formulation, Ferriprox, L1.

At a glance

Generic nameDeferiprone oral solution
Also known asDFP, Deferiprone extended release tablet formulation, Ferriprox, L1
SponsorApoPharma
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Deferiprone oral solution

What is Deferiprone oral solution?

Deferiprone oral solution is a Small molecule drug developed by ApoPharma.

Who makes Deferiprone oral solution?

Deferiprone oral solution is developed and marketed by ApoPharma (see full ApoPharma pipeline at /company/apopharma).

Is Deferiprone oral solution also known as anything else?

Deferiprone oral solution is also known as DFP, Deferiprone extended release tablet formulation, Ferriprox, L1.

What development phase is Deferiprone oral solution in?

Deferiprone oral solution is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing